#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
President Trump’s Executive Order 14370 aims to expand medical cannabis and cannabidiol research by reducing regulatory barriers that have historically limited clinical investigations in the United States. The order addresses longstanding constraints imposed by the Controlled Substances Act scheduling of cannabis, which has severely restricted the number of DEA-approved research facilities and the availability of research-grade cannabis materials for scientists. As medical cannabis use continues to grow in states like West Virginia, this executive action creates an opportunity to generate rigorous clinical evidence regarding cannabis efficacy and safety across various conditions, potentially informing future prescribing guidelines and clinical decision-making. For clinicians currently recommending cannabis products to patients, expanded research could provide much-needed high-quality data to support or refine clinical recommendations beyond the limited existing evidence base. The practical takeaway for clinicians is that this regulatory shift may soon improve access to credible clinical evidence to guide cannabis recommendations, though practitioners should continue counseling patients about current knowledge limitations until robust clinical trial data emerges.
“What we’re seeing in West Virginia and across the country is a growing patient population that’s already using cannabis therapeutically, often without robust clinical guidance, so the real opportunity here isn’t to promote or restrict cannabis but to finally conduct the rigorous research that lets us answer the questions our patients are already asking us in the exam room.”
🔬 West Virginia’s growing medical cannabis use, coupled with the federal research executive order, creates both opportunity and obligation for clinicians to engage thoughtfully with this evolving evidence base. While increased research funding may eventually clarify efficacy and safety for specific conditions, current clinical evidence remains limited and heterogeneous, particularly for many indications beyond chemotherapy-induced nausea and certain seizure disorders. Practitioners should recognize that patients are already using cannabis products in their communities, often with variable product quality, inconsistent dosing, and limited pharmacovigilance data, which complicates the risk-benefit conversation. The challenge for clinical practice is balancing respect for patient autonomy and emerging state-level access with the honest acknowledgment that robust clinical trials in most indications are still pending. Clinicians in states with medical cannabis programs should consider documenting patient use patterns, monitoring for adverse effects and drug interactions, and remaining engaged with the research literature as it
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: